Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171730 · ClinicalTrials.gov registry record · Phase 2
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00171730 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT00171730, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Acromegaly is a rare, serious condition characterized by chronic hypersecretion of growth hormone (GH), generally caused by a GH-secreting pituitary adenoma. The study assessed the long-term safety and efficacy of pasireotide in participants with acromegaly.
Interventions
- DRUG Pasireotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-08-24 |
| Est. Completion | 2013-12-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00171730
The ClinicalTrials.gov registry entry for NCT00171730 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pasireotide is the first listed.
NCT00171730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00171730 about?
NCT00171730 is a clinical study titled "An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly". Acromegaly is a rare, serious condition characterized by chronic hypersecretion of growth hormone (GH), generally caused by a GH-secreting pituitary adenoma. The study assessed the long-term safety and efficacy of pasireotide in participants with acromegaly.
What is the current status of trial NCT00171730?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2004-08-24. Estimated completion is 2013-12-06.
What interventions are being tested in trial NCT00171730?
The interventions under investigation include: Pasireotide (DRUG).
Who is sponsoring clinical trial NCT00171730?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.